- Report
- October 2023
- 146 Pages
Global
From €3411EUR$3,528USD£2,924GBP
€4013EUR$4,150USD£3,440GBP
- Clinical Trials
- April 2024
- 200 Pages
Global
From €3385EUR$3,500USD£2,901GBP
- Report
- April 2020
- 75 Pages
Global
From €3820EUR$3,950USD£3,274GBP
- Report
- November 2021
- 119 Pages
Global
From €4352EUR$4,500USD£3,730GBP
- Drug Pipelines
- November 2019
- 60 Pages
Global
From €3385EUR$3,500USD£2,901GBP
- Report
- April 2024
- 74 Pages
Global
From €3500EUR$3,877USD£3,105GBP
- Report
- May 2022
- 59 Pages
Global
From €2418EUR$2,500USD£2,072GBP
- Report
- May 2022
- 38 Pages
Global
From €2418EUR$2,500USD£2,072GBP
- Report
- May 2022
- 51 Pages
Global
From €2418EUR$2,500USD£2,072GBP
- Report
- November 2021
- 747 Pages
Global
From €3868EUR$4,000USD£3,315GBP
The Carcinoembryonic Antigen (CEA) market is a subset of the drug discovery industry. CEA is a biomarker used to detect and monitor certain types of cancer. It is used to diagnose and monitor the progression of colorectal, pancreatic, and other gastrointestinal cancers. CEA is also used to monitor the effectiveness of cancer treatments.
CEA-based drug discovery is a rapidly growing field, with many companies developing new treatments and diagnostic tools. Companies are developing CEA-based drugs to target specific cancer types, as well as to improve the accuracy of cancer diagnosis. Additionally, companies are developing CEA-based diagnostics to detect cancer earlier and more accurately.
Some companies in the CEA market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more
